$5.8B for Nothing: AbbVie Shelves Stemcentryx Drug After Latest Flop

$5.8B for Nothing: AbbVie Shelves Stemcentryx Drug After Latest Flop

Source: 
Xconomy
snippet: 

AbbVie has officially waved the white flag on the cancer drug that triggered its $5.8 billion buyout of Stemcentryx a few years ago.

North Chicago, IL-based AbbVie (NYSE: ABBV) said that rovalpituzumab tesirine, or Rova-T, failed another clinical trial—this time a Phase 3 study, MERU, testing the drug as a maintenance therapy in patients with newly diagnosed small cell lung cancer (SCLC).